* Health Catalyst Inc HCAT.OQ HCAT.O is expected to show
a
rise in quarterly revenue when it reports results on February
28.
* The South Jordan Utah-based company is expected to report
a
5.5% increase in revenue to $68.256 million from $64.72 million
a year ago, according to the mean estimate from 14 analysts,
based on Refinitiv data. The company's guidance on November 8
2022, for the period ended December 31, was for revenue between
$66.90 million and $68.90 million.
* Refinitiv's mean analyst estimate for Health Catalyst Inc
is
for a loss of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 7
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Health
Catalyst
Inc is $15, above its last closing price of $13.48.
The company's guidance on November 8 2022 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between 66.9 million and -100
thousand (USD).
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.18 -0.19 -0.13 Beat 32.8
Jun. 30 2022 -0.09 -0.10 -0.03 Beat 70.2
Mar. 31 2022 -0.09 -0.11 -0.06 Beat 47.6
Dec. 31 2021 -0.16 -0.21 -0.19 Beat 10.2
Sep. -0.21 -0.22 -0.18 Beat 17.2
30 2021
Jun. 30 2021 -0.14 -0.14 0.00 Beat 100
Mar. 31 2021 -0.13 -0.15 -0.06 Beat 59.2
Dec. 31 2020 -0.17 -0.19 -0.16 Beat 17.1
This summary was machine generated February 25 at 03:06 GMT.
All figures in US dollars unless otherwise stated